德谷胰岛素对比地特胰岛素联合门冬胰岛素治疗妊娠期1型糖尿病(EXPECT):一项开放标签、多国、随机对照非劣效性试验
EXPECT试验在14国56个中心纳入225例1型糖尿病孕妇或计划妊娠者,随机接受德谷胰岛素或地特胰岛素联合门冬胰岛素。德谷组分娩前最后计划HbA1c为6.2%,地特组为6.3%,估计治疗差异-0.11%(95%CI -0.31至0.08),非劣效性成立,未观察到额外安全性问题。
要点
- 德谷胰岛素在1型糖尿病孕妇中分娩前HbA1c非劣效于地特胰岛素。
- 德谷组与地特组分娩前HbA1c估计治疗差异为-0.11%(95%CI -0.31至0.08)。
- 与地特胰岛素相比,德谷胰岛素未观察到额外安全性问题。
核心结论
- 在妊娠期1型糖尿病患者中,德谷胰岛素被判定非劣效于地特胰岛素。
研究设计与样本
- EXPECT为开放标签、多国、随机对照非劣效性试验,在14个国家56个中心开展。
- 纳入年龄至少18岁、孕周8周+0天至13周+6天或计划妊娠的1型糖尿病女性,按1:1随机分配至德谷胰岛素(100 U/mL)每日一次或地特胰岛素(100 U/mL)每日一至两次,均联合餐时门冬胰岛素(100 U/mL)皮下注射。
- 妊娠者自随机化起接受试验药物至整个妊娠期及产后28天(治疗结束),随机化时未妊娠者在受孕前开始试验药物。
- 主要终点为分娩前最后计划HbA1c测量值,德谷对比地特的非劣效界值为0.4%。
- 主要终点在所有随机分配且试验期间妊娠的参与者中评估,安全性在所有随机分配、试验期间妊娠且至少暴露一剂试验药物的参与者中评估。
主要发现
- 2017年11月22日至2019年11月8日,筛查296例女性,225例随机分配至德谷组(n=111)或地特组(n=114)。
- 妊娠基线平均HbA1c德谷组为6.6%(SD 0.6%;约49 mmol/mol;SD 7 mmol/mol),地特组为6.5%(0.8%;约48 mmol/mol;9 mmol/mol)。
- 分娩前最后计划平均HbA1c德谷组为6.2%(SE 0.07%;约45 mmol/mol;SE 0.8 mmol/mol),地特组为6.3%(SE 0.07%;约46 mmol/mol;SE 0.8 mmol/mol)。
- 估计治疗差异为-0.11%(95%CI -0.31至0.08);-1.2 mmol/mol(95%CI -3.4至0.9);非劣效性P<0.0001,确认非劣效性。
- 与地特胰岛素相比,德谷胰岛素未观察到额外安全性问题。
关键数值与推荐
- 主要终点非劣效界值为德谷对比地特的HbA1c差异0.4%。
- 分娩前最后计划HbA1c估计治疗差异-0.11%(95%CI -0.31至0.08),非劣效性P<0.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Insulin degludec (degludec) is a second-generation basal insulin with an improved pharmacokinetic-pharmacodynamic profile compared with first-generation basal insulins, but there are few data regarding its use during pregnancy. In this non-inferiority trial, we aimed to compare the efficacy and safety of degludec with insulin detemir (detemir), both in combination with insulin aspart (aspart), in pregnant women with type 1 diabetes. METHODS: This open-label, multinational, randomised, controlled, non-inferiority trial (EXPECT) was conducted at 56 sites (hospitals and medical centres) in 14 countries. Women aged at least 18 years with type 1 diabetes who were between gestational age 8 weeks (+0 days) and 13 weeks (+6 days) or planned to become pregnant were randomly assigned (1:1), via an interactive web response system, to degludec (100 U/mL) once daily or detemir (100 U/mL) once or twice daily, both with mealtime insulin aspart (100 U/mL), all via subcutaneous injection. Participants who were pregnant received the trial drug at randomisation, throughout pregnancy and until 28 days post-delivery (end of treatment). Participants not pregnant at randomisation initiated the trial drug before conception. The primary endpoint was the last planned HbA1c measurement before delivery (non-inferiority margin of 0·4% for degludec vs detemir). Secondary endpoints included efficacy, maternal safety, and pregnancy outcomes. The primary endpoint was assessed in all randomly assigned participants who were pregnant during the trial. Safety was assessed in all randomly assigned participants who were pregnant during the trial and exposed to at least one dose of trial drug. This study is registered with ClinicalTrials.gov, NCT03377699, and is now completed. FINDINGS: Between Nov 22, 2017, and Nov 8, 2019, from 296 women screened, 225 women were randomly assigned to degludec (n=111) or detemir (n=114). Mean HbA1c at pregnancy baseline was 6·6% (SD 0·6%; approximately 49 mmol/mol; SD 7 mmol/mol) in the degludec group and 6·5% (0·8%; approximately 48 mmol/mol; 9 mmol/mol) in the detemir group. Mean last planned HbA1c measurement before delivery was 6·2% (SE 0·07%; approximately 45 mmol/mol; SE 0·8 mmol/mol) in the degludec group and 6·3% (SE 0·07%; approximately 46 mmol/mol; SE 0·8 mmol/mol) in the detemir group (estimated treatment difference -0·11% [95% CI -0·31 to 0·08]; -1·2 mmol/mol [95% CI: -3·4 to 0·9]; pnon-inferiority<0·0001), confirming non-inferiority. Compared with detemir, no additional safety issues were observed with degludec. INTERPRETATION: In pregnant women with type 1 diabetes, degludec was found to be non-inferior to detemir. FUNDING: Novo Nordisk.
引用
- Mathiesen ER, Alibegovic AC, Corcoy R, et al. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial. Lancet Diabetes Endocrinol. 2023. PMID: 36623517. doi:10.1016/S2213-8587(22)00307-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。